Instituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Instituto Colombiano de Medicina Tropical-Universidad CES, Medellín, Colombia.
Travel Med Infect Dis. 2022 Sep-Oct;49:102427. doi: 10.1016/j.tmaid.2022.102427. Epub 2022 Aug 10.
Although more than half of the world's population is already vaccinated, the appearance of new variants of concern puts public health at risk due to the generation of new immunogens against the virus as a crucial and relevant strategy in the control of these new variants.
A preclinical study used a potential vaccine candidate (RBD, SARS-CoV-2). Four groups of BALB/c mice were used, a control group, an adjuvant group, a group inoculated with one dose of RBD subunit protein, and the fourth group inoculated with two doses of RBD subunit protein.
No inflammatory or cellular changes were shown in the mice's anatomopathological evaluation. Higher kinetics and 75% seroconversion were obtained in the mice inoculated with two doses of RBD (P < 0.0001).
The application of two doses of the RBD vaccine candidate in BALB/c mice proved safe and immunogenic against SARS-CoV-2.
尽管世界上超过一半的人口已经接种了疫苗，但新出现的令人关注的变异株仍会对公众健康构成威胁，因为针对病毒产生新的免疫原是控制这些新变异株的关键和重要策略。
一项临床前研究使用了一种潜在的疫苗候选物（RBD，SARS-CoV-2）。使用了四组 BALB/c 小鼠，对照组、佐剂组、接种一剂 RBD 亚单位蛋白的组和接种两剂 RBD 亚单位蛋白的组。
在小鼠的解剖病理学评估中未显示出炎症或细胞变化。接种两剂 RBD 的小鼠获得了更高的动力学和 75%的血清转化率（P < 0.0001）。
在 BALB/c 小鼠中应用两剂 RBD 疫苗候选物被证明是安全的，并对 SARS-CoV-2 具有免疫原性。
